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Searching the second hit in patients 
with inherited retinal dystrophies 
and monoallelic variants in ABCA4, 
USH2A and CEP290 by whole-gene 
targeted sequencing
María González-del Pozo1,2, Marta Martín-Sánchez1, Nereida Bravo-Gil1,2, 
Cristina Méndez-Vidal1,2, Ángel Chimenea  1, Enrique Rodríguez-de la Rúa3,4, 
Salud Borrego1,2 & Guillermo Antiñolo  1,2
Inherited Retinal Dystrophies are clinically and genetically heterogeneous disorders affecting the 
photoreceptors. Although NGS has shown to be helpful for the molecular diagnosis of these conditions, 
some cases remain unsolved. Among these, several individuals harboured monoallelic variants in 
a recessive gene, suggesting that a comprehensive screening could improve the overall diagnosis. 
In order to assess the contribution of non-coding variations in a cohort of 29 patients, 25 of them 
with monoallelic mutations, we performed targeted NGS. The design comprised the entire genomic 
sequence of three genes (USH2A, ABCA4 and CEP290), the coding exons of 76 genes and two disease-
associated intronic regions in OFD1 and PRPF31. As a result, likely causative mutations (8 novel) were 
identified in 17 probands (diagnostic rate: 58.62%), including two copy-number variations in USH2A 
(one deletion of exons 22–55 and one duplication of exons 46–47). Possibly damaging deep-intronic 
mutations were identified in one family, and another with a monoallelic variant harboured causal 
mutations in a different locus. In conclusion, due to the high prevalence of carriers of IRD mutations 
and the results obtained here, sequencing entire genes do not seem to be the approach of choice for 
detecting the second hit in IRD patients with monoallelic variants.
Inherited Retinal Dystrophies (IRDs) are a group of rare disorders characterized by the progressive loss of pho-
toreceptors in the retina, with a prevalence of 1 in 3,000 individuals worldwide1. Depending on the first photo-
receptor cell affected, IRDs are subdivided in rod-cone and cone-rod degenerations. The most common form 
of IRDs is Retinitis Pigmentosa (RP), a rod-cone disease defined by a primary death of rods, which results in 
night blindness and constriction of the visual field. Later in life, loss of cones leads to a decreased visual acuity2. 
RP can be inherited as an autosomal dominant (adRP), autosomal recessive (arRP) or X-linked (xlRP) trait, but 
in a large percentage of cases the mode of inheritance is unknown due to absence of family history (simplex RP, 
sRP). In other pathologies like cone-rod dystrophies (COD), cones degenerate first, whereas in Leber congen-
ital amaurosis (LCA) both types of photoreceptors are damaged simultaneously3. Maculopathies like Stargardt 
disease (STGD) are defined by loss of central vision and accumulation of yellow flecks deposits around the mac-
ula4,5. There are also syndromic pathologies related to IRDs such as Usher syndrome (USH), in which RP is 
accompanied by congenital hearing impairment2. Several of these conditions share some features, which leads 
to overlapping phenotypes. Moreover, IRDs are characterized by huge phenotypic variability, in which clinical 
features, age of onset and disease progression can vary from patient to patient, even in the same family (inter- and 
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intra-familial variability)6,7. Furthermore, IRDs are one of the most genetically heterogeneous disorders. To date, 
more than 300 genes have been associated (RetNet; https://sph.uth.edu/retnet/, accessed July 2018). In addition, 
mutations in a single gene can be associated with a broad phenotypic spectrum and a specific phenotype can be 
caused by mutations in multiple genes8.
Next-generation sequencing (NGS) resulted in an improvement of the diagnostic rate of this group of heter-
ogeneous disorders9–11. However, even though these strategies show high efficacy in a large proportion of cases, 
around 40–50% of cases remain unsolved9,12. Deep-intronic variants, large rearrangements that escape genetic 
detection or currently unknown IRDs genes may explain these cases13. In order to increase the diagnostic rate of 
this group of disorders, other genomic regions not routinely analyzed must be considered.
Aberrant splicing is a well-known disease-causing mechanism. In fact, it is estimated that a significant per-
centage of mutations related to monogenic pathologies have an effect on splicing14,15. Indeed, deep-intronic muta-
tions in ABCA416,17, CEP29018, USH2A19, CHM20,21, PRPF3122 or OFD123 have been described as disease-causing 
in IRDs. Furthermore, mutations in genes coding for spliceosome components have been found in patients with 
RP24,25, which enlightens the importance of alternative splicing in this condition. Structural variants, including 
CNVs, have also been described as a relevant cause of disease26. Specifically in IRDs, duplications and deletions 
have been linked to the development of syndromic and non-syndromic cases20,27–29. These mutations are easier 
to detect by whole-genome or whole gene sequencing, as coding and non-coding elements analysis allows the 
identification of the accurate size and both breakpoints of CNVs.
Here we applied a targeted gene panel covering the entire genomic region of three genes (ABCA4, USH2A 
and CEP290) and the coding exons of 76 additional genes for the molecular analysis of 29 IRDs patients with 
simplex or suspected autosomal recessive inheritance. For 25 of them, other methods have previously succeeded 
in identifying a heterozygous variant in one of these genes. Our study aimed to find a second variant in the same 
gene to explain the patients’ phenotype by compound heterozygous inheritance. The diagnostic rate was 58.62%% 
(17/29), of which 14 cases (~77.7%) were solved by the identification of USH2A mutations.
Results
Clinical features. All analyzed families (n = 29) were of Spanish origin. Index patients received a well-de-
fined clinical diagnosis, which included either RP, USH type II (USHII), STGD, LCA or COD. Available clinical 
findings of the index patients of the likely genetically diagnosed families are reported in Table 1. The presumed 
underlying mode of inheritance was either autosomal recessive or simplex in all families. In 10 cases, DNA sam-
ples from additional family members were used for segregation analysis of the candidate variants.
NGS data quality. The panel design covered 95.3% (1,346,725 bp) of 1,412,505 target bases. The uncov-
ered bases represented 4.7% of the total number of bases, most of them lying in non-coding regions (repeating 
elements: Long terminal repeats, LTRs and Long interspersed nuclear elements, LINEs). The specific uncovered 
bases of the genes ABCA4, CEP290 and USH2A are provided in Supplementary Table S1. Only one exonic region 
in exon 15 (ORF15) of RPGR remained uncovered (98–145 bp, depending on the patients). The overall mean 
coverage was 809X with 100% of captured bases covered, except for individual II:6 of family R, whose coverage 
dropped to 96.6% due to a large homozygous deletion (Fig. 1). NGS performed on an Illumina MiSeq or NextSeq 
systems achieved on average 9,828,453 reads per run of which 8,213,528 were mapped on target (82.73%).
Validation of the panel. Twenty-five out of the 29 cases included in this study carried heterozygous 
mutations previously detected by other techniques (Table 2), and so, they were used as positive controls for our 
approach. The application of the data analysis pipeline allowed the accurate re-detection of all the known variants, 
indicating a mutation detection rate of 100%.
Identification and assessment of candidate variants. In order to identify likely disease-causing vari-
ants for each sample, we conducted a stepwise mutation detection protocol as previously described9,30 with some 
modifications: heterozygous mutations in genes with one previous detected variant were prioritized and new 
variants, including CNVs, were looked for in non-coding regions (deep-intronic and splicing mutations) and 
coding regions (synonymous variants). Intronic variants were analyzed with in silico tools for their potential effect 
on splicing. If no mutations were found, variants in other genes were assessed as we described in the Methods 
section.
Sequencing of the gene panel led to the identification of a mean of 2,349 potential variants per patient. After 
filtering out common polymorphisms with MAF > 0.015 in any of the variant databases queried, including 1,000 
Genomes, ExAC and EVS, an average of 314 rare variants per sample remained, of which a range from 1 to 4 were 
prioritized as described above to be co-segregated by Sanger sequencing.
As a result, 31 pathogenic mutations were identified as likely causative in 17 probands (six familial cases and 
11 simplex cases) (Supplementary Fig. S1) achieving a diagnostic rate of 58.62% (Table 1). The most frequently 
mutated gene in this study was USH2A (Table 3), and the most prevalent mutation was p.Cys759Phe. We found 
this mutation in nine patients, always in a compound heterozygous state with a deleterious allele, and only in 
non-syndromic RP patients (Fig. 2). All novel and known sequence variants of the genetically diagnosed patients 
have been submitted to the Leiden Open Variation Database, LOVD (https://databases.lovd.nl/).
Among the candidate variants, two of them were CNVs in USH2A, comprising one homozygous dele-
tion of exons 22–55 (c.4628–2287_10939 + 3867del) and one heterozygous duplication of exons 46 and 47 
(c.9055 + 100_9371 + 5544dup) (Fig. 1). Furthermore, we also detected 18 missense, four frameshift, three non-
sense, three intronic-splicing and one synonymous variant located in the exonic canonical splice site (Table 1). 
Eight of the 31 variants were novel and absent in public databases (ClinVar, LOVD, Pubmed, dbSNP, ExAC, 
GnomAD, EVS, 1000G and CSVS). Specifically, we detected three homozygous (probands of families B, D and 
www.nature.com/scientificreports/
3SCIEnTIFIC REPORTS |  (2018) 8:13312  | DOI:10.1038/s41598-018-31511-5
Family 
(index)
Onset age: First 
symptom
Extraction age: 
Symptoms
Fundus 
examination Clin. Diagn. Gene
[Allele 1] [Allele 2]
Clin. Significance 
(Known v.)*
Segr 
An.
Other features and 
commentsReference Reference
Pathog. Scores (Novel 
v.)**
A (II:1)
10y: VAD. 34y: 
VA CF; NB; VFR; 
CVA;
Macular 
pigment 
deposits
STGD ABCA4 M1: c.4253 + 5G > A; r.(spl?)68
M2: c.5898G > A; r.(spl?) 
p.Glu1966Glu
This study
M1 Clinvar: Pathog.
Yes Photoph.M2 MT: Damaging
NNS: Donor Lost
HSF: Site Broken
B (II:1)
2y: Intense 
photoph. 5y: VAD; 
CVA.
No apparent 
changes COD
CNGB3 M3: c.1148del; p.Thr383Ilefs*1353 M3 Clinvar: CIP [Pathog.(14); VUS(1)] Yes
Consang.; 
Micronystagmus; 
Amblyopia; 
HypermetropiaABCA4
m4: c.466A > G; p.Ile156Val 
(†)44
m4
Clinvar: VUS —
C (II:1) 40y: NB69y: VFC.; VAD.
Typical of RP 
at a later stage; 
RPE atrophy
sRP
FSCN2
m5: c.1345 + 6_1345 + 10dup; 
r.(spl?);
This study
m5
MT: Damaging
NNS: No changes
HSF: No impact
NA
Catar.
ABCA4 m6: c.6148G > C; p.Val2050Leu (†)69
m6 Clinvar: CIP [Ben.
(1); Likely ben.(4); Likely 
pathog.(3); Pathog.(1)]
NA
D (II:1)
1y: NB
29y: Ring 
scotoma; VAD; 
CVA.
Punctate yellow-
white deposits 
in the macula; 
Peripapillary 
atrophy
LCA LRAT M7: c.163C > G; p.Arg55GlyThis study
M7
MT: Damaging
SIFT: Damaging
Polyph: Damaging
Yes Photoph.; Consang.
E (II:4)
18y: NB
24y: Tunnel vision 
(central island, 
30°)
RPE atrophy, 
bone spicule 
pigmentation
sRP
USH2A M8: c.1560C > A; p.Cys520*This study
M9: c.2276G > T; 
p.Cys759Phe (†)62
M8
MT: Damaging
NA
None
M9 Clinvar: CIP [Likely 
pathog.(6); Pathog.(7); 
VUS(2)]
USH2A m10: c.6590 C > T; p.Thr2197Ile20
m10 Clinvar: CIP [Likely 
Pathog.(1); VUS(1)] NA
F (II:3)
25y: NB
39y: VFC; Discrete 
VAD.
Bone spicule 
pigmentation in 
the periphery
sRP USH2A M11: c.2167 + 5G > A; r.(spl?)70
M9: c.2276G > T; 
p.Cys759Phe (†)62
M11 Clinvar: Pathog71
NA Myopia; Astigmatism
M9: see above
G (II:1)
18y: VF constr.
48y: NB; Tunnel 
vision; VAD
Typical of RP sRP USH2A M9: c.2276G > T; p.Cys759Phe (†)62
M12: c.12574 C > T; 
p.Arg4192Cys72
M9: see above
NA Incipient catar.; TritanopiaM12 Clinvar: CIP [Likely 
pathog.(2); VUS(1)
H (II:3)
12y: NB
33y: VFC.; VAD; 
CVA
Bone spicule 
pigmentation in 
the periphery
arRP + SNHL USH2A M9: c.2276G > T; p.Cys759Phe (†)62
M13: c.12457del; 
p.Ala4153Profs*14
M9: see above
Yes
Progressive and bilateral 
SNHL (33y); Father with 
SNHL. Brother with 
M13
HGMD: Pathog.
I (II:2)
30y: VF constr.
50y: NB; VF island 
5° central; VAD
Typical of RP sRP USH2A M9: c.2276G > T; p.Cys759Phe (†)62
M14: c.9799T > C; 
p.Cys3267Arg73
M9: see above
NA Catar.; Photoph.M14 Clinvar: Likely 
pathog.
J (II:1) 19y: NB30y: VFC. Typical of RP sRP USH2A
M9: c.2276G > T; 
p.Cys759Phe(†)62
M15: c.11156G > A; 
p.Arg3719His72
M9: see above
NA None
M15 Clinvar: Pathog.
K (II:1)
12y: NB and VFR.
15y: VF Central 
island, 10°
Decrease 
in retinal 
thickness; No 
sRP (sp) USH2A M9: c.2276G > T; p.Cys759Phe (†)62
M16: c.14011G > T; 
p.Glu4671*
This study
M9: see above
Yes NoneM16
MT: Damaging
L (II:1) 43y: NB53y: VFC; VAD. Typical of RP sRP USH2A
M9: c.2276G > T; p.Cys759Phe 
(†)62
M14: c.9799T > C; 
p.Cys3267Arg73
M9: see above
Yes Catar.
M14: see above
M (II:1) 14y: NB28y: VFC.; VAD. Typical of RP USH USH2A
M17: c.2299del; 
p.Glu767Serfs*21 (†)74
M18: c.15089C > A; 
p.Ser5030*75
M17
Clinvar: Pathog./Likely 
pathog. Yes
Nystagmus; Bilateral 
SNHL
M18 LOVD: Pathog.
N (II:12) 39y: VFC.49y: NB Typical of RP arRP USH2A
M17: c.2299del; 
p.Glu767Serfs*21 (†)74
M19: c.4325T >C; 
p.Phe1442Ser76
M17: see above
NA Diabetes mellitus(Type II)M19 LOVD: Likely 
Pathog.
O (II:1)
7y: NB
58y: Tunnel vision 
(5°); VAD.; CVA
Bone spicule 
pigmentation 
and pallor of the 
sRP USH2A M20: c.907C > A; p.Arg303Ser61
M9: c.2276G > T; 
p.Cys759Phe (†)62
M20 LOVD: Likely 
Pathog. NA Photoph.;Catar.; Aphakia; Glaucoma
M9: see above
P (II:9)
13y: NB
35y: Tunnel vision 
(central island, 
Typical of RP USH USH2A M20: c.907C > A; p.Arg303Ser (†)61
M21: Duplication
Ex 46–47c.9055 + 
100_9371 + 5544dup; p.?
M20: see above
Yes
Strabismus; Astigmatism; 
Photoph.;Catar.; Two 
sisters with isolated arRP
M21
MT: Damaging
Q (II:4) 33y: NB34y: VFC
Typical of RP at 
a later stage arRP USH2A
M20: c.907C > A; p.Arg303Ser 
(†)61
M22: c.12067–2A >  
G; r.spl77
M20: see above
Yes Incipient catar. Shiny ILMM22
Clinvar: Pathog.
Continued
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R) and 28 compound heterozygous mutations in autosomal recessive IRDs genes. However, segregation analysis 
could only be performed in 10 out of 17 families, due to the difficulty in recruiting additional family members in 
simplex cases. In the remaining patients, candidate variants were presumed to be disease-causing since they cor-
related with their specific phenotype and they met the established pathogenicity criteria (see Methods section). 
In this study, we emphasize the importance of intronic and synonymous variants and their effect on splicing 
processes, which let us diagnosed two cases.
Besides the 31 disease causing mutations, we detected one heterozygous mutation in an autosomal dominant 
IRDs-associated gene (FSCN2, c.1345 + 6_1345 + 10 dup) in one proband affected of simplex RP (Family C-II:1). 
Nevertheless, segregation analysis could not be performed in this family and the in silico predictions failed to val-
idate this mutation as a splice-altering variant (Table 1). Interestingly, this patient was also a carrier of the ABCA4 
allele (p.Val2050Leu) reported as variant with conflicting interpretations of pathogenicity in the Clinvar database. 
Therefore, additional studies are needed to ascertain the genetic cause of the disease in this family.
Deep-intronic variants assessment. One of the main objectives of this study was to gain knowledge 
of the contribution of deep-intronic variants in our population. After analyzing the genomic data, only those 
deep-intronic variants that fulfilled the selection criteria to be considered causative mutations were selected 
to be segregated, when possible. A total of 5 variants were found to pass the standards: m33 (USH2A c.6326–
17446_6326-17439dup) in family B-II:1, m36 (ABCA4 c.66 + 2044G > A) in family X-II:1, m37 (CEP290 c.3104-
238 T > G) in family Z-II:1 and m39 (USH2A c.6806-810 A > G) and m40 (USH2A c.6050-8058G > C) in family 
S-II:1 (Supplementary Fig. S1). Variants m33, m36 and m37 do not segregate with the disease, as they were 
in cis with the previously found mutation in these patients. Regarding the other family (Family S), although 
segregation analysis could not be conducted, both variants (m39: USH2A c.6806-810 A > G and m40: USH2A 
c.6050-8058G > C) are predicted to induce the activation of a cryptic donor/acceptor site respectively. Moreover, 
a very low frequency in the queried databases was retrieved for these changes (0 and 13 heterozygous carriers in 
GnomAD, respectively).
Detection of the second mutation in patients with monoallelic variants. Among the families with 
a monoallelic variant in one of the genes included in the panel, 15 harboured a single previously detected variant 
in USH2A, eight in ABCA4 and two in CEP290 (Table 2). Remarkably, 13 out of 15 of the families with a previous 
Family 
(index)
Onset age: First 
symptom
Extraction age: 
Symptoms
Fundus 
examination Clin. Diagn. Gene
[Allele 1] [Allele 2]
Clin. Significance 
(Known v.)*
Segr 
An.
Other features and 
commentsReference Reference
Pathog. Scores (Novel 
v.)**
R (II:6)
10y: NB
62y: VFC; LP; 
Legal Blindness
Typical of RP USH USH2A
M23: Deletion  
Ex 22–55c.4628-2287_10939 + 3867del; p.?
This study
M23
MT: Damaging Yes
Catar.; Nystagmus; 
Bilateral SNHL
S (II:1) 14y: NB30y: VDA, VFR Typical of RP sRP USH2A
m33: c.5363A > G; 
p.Asp1788Gly30
m39: c.6806-810A > G; r.?
m40: c.6050-8058G > C; r.?
m33
MT: Benign
SIFT: Benign
Polyph: Possibly 
Damaging
No Myopia, astigmatism
m39
MT: Benign
NNS: New donor
HSF: New Donor
m40
MT: Benign
NNS: New acceptor
HSF: New acceptor
Table 1. Clinical and genetic findingsin the index patients of the likely characterized families. *The clinical 
significance of the known variants identified has been obtained using Clinvar, LOVD or HGMD databases. 
**In order to predict the impact on the protein’s function of the novel variants, we have conducted in silico 
analysis using MutationTaster (MT) for all kind of mutations, SIFT and Polyphen (Polyph) for the missense 
variant, and NNSPLICE (NNS) and HSF for the splice site variants. Alt: Alteration; arRP: Autosomal recessive 
Retinitis Pigmentosa; Catar.: cataracts; CF: Counting fingers; CIP: Conflicting interpretations of pathogenicity; 
Clin: Clinical; COD: Cone Dystrophy; CVA: Colour vision Alteration; D: Damaging or Disease causing; DL: 
Donor lost; ERM: Epiretinal membrane; LCA: Leber Congenital Amaurosis; LP: Light perception; ILM: Internal 
limiting membrane; MT: MutationTaster; N: Neutral; NA: Not available; NB: Night Blindness; NR: No response; 
Pathog.: Pathogenicity; Photoph.: Photophobia; Polyph: Polyphen; RP: Retinitis Pigmentosa; RPE: Retinal 
pigment epithelium; SB: Site broken; Segr. An.: Segregation Analysis; SNHL: Sensorineural hearing loss; sp: 
sine pigmento; sRP: Simplex RP; STGD: Stargardt disease; USH: Usher Syndrome; v: variant; VA: Visual acuity; 
VAD: Visual Acuity Decresed; VFC: Visual Field Contriction; VFR: Visual Field Reduction; VUS: Variant of 
unknown significance; y: Years;(w.a.): when available; (†): Variant previously detected by other techniques.
Uppercase “M#” indicates likely causal mutations, lowercase “m#” indicates other variants. Fundus typical of RP 
comprised: Bone spicule pigmentation, narrowed vessels and pallor of the optic disc.
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USH2A variant were genetically solved by the identification of a second hit in the same gene. Interestingly, family 
S harbours, besides a missense mutation (c.5363 A > G, p.Asp1788Gly) in USH2A, two deep-intronic variants 
that, although additional studies are needed, might be causative.
Figure 1. Detection of CNVs in USH2A using our NGS approach. (a) IGV snapshot showing the homozygous 
deletion of exons 22–55 detected in family R-II:6 (Chr1:g.215,949,321_216,272,841del, hg19). The capture 
of whole genomic sequence of USH2A allowed us to determinate the CNVs breakpoints. (b) Schematic 
representation of the mutated gDNA sequence and Sanger sequencing of the breakpoint area (orange arrows) 
confirming the USH2A deletion (c.4628-2287_10939 + 3867del; NM_206933). (c) IGV snapshot showing 
the heterozygous duplication of exons 46–47 (Chr1:g.216,005,789_216,019,066dup, hg19) detected in family 
P-II:9 versus a control sample. The heterozygous duplication can be inspected visually using IGV paying special 
attention to (i) a sharp increase in the coverage and (ii) changes in the allele ratios of all the SNPs within the 
duplicated interval from ~50:50 to ~67:33 unmasking the presence of a total of three copies. (d) Schematic 
representation of the mutated gDNA sequence and Sanger sequencing of the breakpoint area (orange arrows) 
confirming the USH2A tandem duplication of exons 46 and 47 (c.9055 + 100_9371 + 5544dup; NM_206933).
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However, the diagnostic yield dropped in families with a known variant in ABCA4 and CEP290, since the 
second potentially causative mutations were not detected in these genes. Of note, one of the cases (Family B) with 
a known ABCA4 mutation (c.466 A > G; p.Ile156Val) was solved by the identification of a homozygous likely 
disease-causing mutation in another gene: CNGB3 (c.1148del; p.Thr383Ilefs*13) (Table 1).
Clinical heterogeneity of USH2A mutations. In our study, we found the USH2A p.Cys759Phe allele 
in compound heterozygosis in 9 patients with non-syndromic RP (Fig. 2). Three patients who received a USHII 
diagnosis harboured a combination of one nonsense and one frameshift mutation (family M), a homozygous 
CNV (family R) and one CNV and a missense mutation (family P) in USH2A. Remarkably, not all the affected 
members of the family P fulfilled the diagnostic criteria of USH, since two affected siblings (II:1 and II:7) exhib-
ited a less severe phenotype consisting of non-syndromic RP (Supplementary Fig. S1). Another family with a 
significant intrafamilial variability was family H. In this family, only two of the three affected siblings (II:3 and 
II:4) suffered from RP and hearing loss (Table 1). However, the hearing loss was more likely to have a different 
Family ID (index) Clinical diagnosis Previous variants Previous studies
Second variant 
in the same gene Solved with this panel
A (II:1) STGD — None — Yes (ABCA4)
B(II:1) COD m4:ABCA4 c.466A > G; p.Ile156Val
Complete sequencing by NGS of coding 
exons of ABCA4 and CRX (External 
genetics laboratory - Imegen, S.L.)
No Yes (CNGB3)
C (II:1) sRP and unilateral maculopathy m6:ABCA4 c.6148G > C; p.Val2050Leu Targeted Sequencing Panel
30 No Unknown (FSCN2)
D (II:1) LCA — None — Yes (LRAT)
E (II:4) sRP M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
F (II:3) sRP M9:USH2A c.2276G > T; p.Cys759Phe Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] Yes Yes
G (II:1) sRP M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
H (II:3) arRP M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
I (II:2) sRP M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
J (II:1) sRP M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
K (II:1) sRP sine pigmento M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
L (II:1) sRP M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
M (II:1) USHER M17: USH2A c.2299del; p.Glu767Serfs*21 Sanger Sequencing of USH2A exon 13 Yes Yes
N (II:12) arRP M17: USH2A c.2299del; p.Glu767Serfs*21 Genotyping microarray for arRP (584 known variants, Asper Biotech, Ltd) Yes Yes
O (II:1) sRP M9:USH2A c.2276G > T; p.Cys759Phe Sanger Sequencing of USH2A exon 13 Yes Yes
P (II:9) USHER M20:USH2A c.907 C > A; p.Arg303Ser Genotyping microarray for arRP (584 known variants, Asper Biotech, Ltd) Yes Yes
Q (II:4) arRP M20:USH2A c.907 C > A; p.Arg303Ser Targeted Sequencing with the same panel as30 [Bravo-Gil et al., 2017] Yes Yes
R (II:6) USHER — None — Yes (USH2A)
S (II:1) sRP m33:USH2A c.5363A > G; p.Asp1788Gly Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No Unknown (USH2A)
T (II:1) sRP m26:ABCA4 c.5881G > A; p.Gly1961Arg//m27:CEP290 c.2691A > G; p.Ile897Met
Targeted Sequencing Panel30 [Bravo-Gil 
et al., 2017] No No
U (II:3) sRP m28:ABCA4 c.5882G > A p.Gly1961Glu Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No No
V (II:1) sRP m29:ABCA4 c.5908 C > T; p.Leu1970Phe Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No No
W (II:3) sRP m6:ABCA4 c.6148G > C; p.Val2050Leu Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No No
X (II:1) sRP m6:ABCA4 c.6148G > C; p.Val2050Leu Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No No
Y (II:1) arRP m30:CEP290 c.3517C > A p.Gln1173Lys Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No No
Z (II:1) sRP m31:CEP290 c.4237G > C; p.Asp1413His Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No No
AA (II:4) sRP m32:USH2A c.1486A > G; p.Thr496Ala Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2017] No No
AB (II:1) STGD — None — No
AC (II:3) STGD m4:ABCA4 c.466A > G; p.Ile156Val Targeted Sequencing Panel
30 [Bravo-Gil 
et al., 2016] No No
Table 2. Initial clinical diagnosis and monoallelic variants identified by other approaches in each of the 
probands included in the study. arRP: Autosomal recessive Retinitis Pigmentosa; COD: Cone Dystrophy; LCA: 
Leber Congenital Amaurosis; sRP: Simplex RP; STGD: Stargardt disease. Uppercase “M#” indicates likely causal 
mutations, lowercase “m#” indicates other variants.
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genetic cause since the father (individual I:1) of the index patient (II:3) was affected of progressive and bilat-
eral non-syndromic hearing loss. Additionally, here we describe two USH2A mutations, p.Glu767Serfs*21 and 
p.Arg303Ser, found in patients with syndromic and non-syndromic RP.
Discussion
In this study, we conducted a NGS targeted sequencing approach comprising all exons of 76 retinal disease genes, 
three entire genes (USH2A, ABCA4 and CEP290), and two deep-intronic regions located in OFD1 and PRPF31, to 
identify the genetic cause of 29 Spanish patients of IRDs, most of them carrying a monoallelic variant in USH2A, 
ABCA4 and CEP290.
The molecular diagnosis was achieved in 58.62% of IRDs patients (17/29). This diagnostic yield is in line with 
previous works30 that similarly analyzed population-specific IRDs genes, and it is somewhat higher than other 
studies involving more genes31,32. It demonstrates that a consistent and adapted design of the panel guarantees a 
good diagnostic yield while reducing sequencing costs, time and analytical effort.
In our cohort, we detected 31 likely disease-causing mutations. The majority of them were missense variants 
(58.1%), followed by splicing (12.9%), and frameshift variants (12.9%). Nonsense and CNVs represented 9.6% 
and 6.5%, respectively. The increasing number of reported deep-intronic mutations in IRD genes prompted us 
to include three entire genes in our panel design: ABCA4, USH2A and CEP290. These genes accumulate a high 
number of pathogenic deep-intronic variants reported in the literature18,19,33,34. In this group of patients, five 
deep-intronic variants that met the pathogenicity criteria were detected in four families (Supplementary Fig. S1). 
However, in three of them (families B, X and Z) the segregation analysis discarded their role in the disease aetiol-
ogy. The index patient of family S (II:1) was clinically diagnosed of non-syndromic RP and harboured a rare mis-
sense variant (c.5363 A > G; p.Asp1788Gly) in USH2A previously detected by targeted NGS (Table 2). Regarding 
the missense mutation, only two heterozygous individuals have been identified in GnomAD, and had no entry 
neither in Clinvar nor LOVD. Sequencing the USH2A entire gene allowed the identification of two deep-intronic 
variants (c.6806-810 A > G and c.6050-8058G > C). Although segregation analysis could not be performed, no 
additional variants that could explain the phenotype of this family were identified in other loci. Therefore, addi-
tional studies are needed to ascertain the clinical significance of these variants.
Screening intronic sequences also enables the proper detection of CNVs since it allows the determination of 
structural variants breakpoints at the nucleotide level, as well as the presence of inversions35,36. Recent studies 
have shown that CNVs in genes such as EYS37,38 or USH2A28,39, are indeed a significant event on the appearance 
of IRDs27,40,41. This is in agreement with our results showing the identification and accurate detection of their 
breakpoints of two novel, likely pathogenic, CNVs in USH2A. Therefore, it is highly recommended that the data 
analysis pipeline includes a suitable algorithm for the detection of these complex alleles.
Remarkably, of the 25 patients with previously detected monoallelic variants, 13 carried a second mutated 
allele in the same gene (USH2A). The majority of the unsolved patients carried a previously identified variant 
in ABCA4. This fact can be explained by the polymorphic nature of certain genes, and specifically of certain 
disease-causing reported variants. In the past, when the available genetic testing techniques were based on 
sequencing or genotyping a few exons per sample, detecting a sequence variant was a challenging task and it 
was interpreted as a causal mutation as long as it correlated with family segregation analysis and it was absent in 
100 control individuals. To date, the proliferation of exome and genome sequencing projects and their use in the 
clinical setting have allowed unmasking some of the variants previously described as pathogenic and now con-
sidered as benign changes or at least variants of unknown significance (VUS) in certain populations42,43. In this 
regard, two variants in ABCA4, p.Ile156Val and p.Val2050Leu, have been traditionally considered disease-causing 
mutations44,45. However, an extensive revision of the literature46–48, the relatively high MAF according to 1000G 
(MAF = 0.019 in IBS and 0.029 in PUR respectively) and the fact that both mutations have been reported in cis 
with protein-truncating variants in STGD patients46,49, suggest that the clinical significance of these missense 
changes must be interpreted with caution especially in the context of genetic and reproductive counselling. 
Another explanation for the lack of success in detecting a second mutant allele in ABCA4 may be that, even if 
these changes were certainly pathogenic, they may not be the cause of disease in our patients. This is especially 
relevant in those cases where genotype does not correlate with the phenotype, for example, for STGD associated 
mutations in RP patients. In this regard, the frequency of IRD carriers in the general population is known to be 
relatively high50, as demonstrated by the increased prevalence of IRDs in consanguineous communities51,52. Of 
note, we have detected two patients with the ABCA4 variants p.Ile156Val and p.Val2050Leu, respectively, and 
additional mutations in other loci.
Clinical diagnosis
Solved cases/Total 
number of cases
Mutated genes 
(number of cases)
ar Retinitis Pigmentosa 3/4 USH2A (3)
simplex Retinitis Pigmentosa 8/17 USH2A (8)
Leber congenital amaurosis 1/1 LRAT (1)
Stargardt disease 1/3 ABCA4 (1)
Usher Syndrome 3/3 USH2A (3)
ar Cone dystrophy 1/1 CNGB3 (1)
Table 3. Distribution of the likely causative genes in our IRD cohort. ar: Autosomal recessive.
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The identification of p.Ile156Val in family B can be considered a chance finding. The affected member of 
family B (II:1) harboured the recurrent single base pair deletion in CNGB3, c.1148del; p.Thr383Ilefs*13. This 
mutation is the most common variant underlying achromatopsia (ACH) worldwide53,54, accounting for over 70% 
of all CNGB3 changes and about 40% of all ACH associated alleles55. Additionally, this variant has also been found 
in patients with juvenile macular degeneration56, macular malfunction56 and, recently, cone dystrophy (COD)57. 
Ophthalmologic examination of patient II:1 of family B confirmed the clinical diagnosis of COD. Although the 
pathogenicity of CNGB3 c.1148del (p.Thr383Ilefs*13) seems convincing due to the large amount of supporting 
studies, two homozygous individuals have been detected in healthy control databases, one in ExAC and another 
one in EVS (entry 8:87,656,008AG/A), but the presence of pathogenic variants in healthy individuals has already 
been widely documented43,58.
Likewise, the contribution to the phenotype of the ABCA4 p.Val2050Leu variant in the index patient of fam-
ily C (II:1) is not entirely clear. This patient carries also a heterozygous variant in gene FSCN2. Nevertheless the 
pathogenicity of the FSCN2 mutation could not be ascertained due to the lack of family members for segregation 
studies and the poor results of the in silico predictors (Table 1). Moreover, the association of this gene with IRDs is 
controversial59,60. Therefore, additional studies will be required to diagnose this simplex patient.
Interestingly, two families (F and Q) which were previously assessed with a customized panel are now genet-
ically explained with a second mutation in USH2A (Table 2). The second hits consisted of both intronic variants 
(c.2167 + 5G > A; r.(spl?) and (c.12067-2 A > G; r.spl, respectively. Both variants should have been detected by 
the previous panel approach, but likely, they were bioinformatically filtered out due to the presence of duplicates.
In our cohort, the USH2A variant p.Cys759Phe was the most commonly mutated allele. Accordingly with other 
studies performed worldwide, this mutation is one of the most prevalent USH2A variants associated, in almost 
all of the cases, with non-syndromic RP61,62. Additionally, p.Cys759Phe variant has been frequently detected in 
compound-heterozygous state accompanied by a deleterious allele, while homozygous cases are rare and have been 
the subject of controversy42. In order to assess the hypothesis that the p.Cys759Phe variant is not pathogenic per se 
but it would be acting in cis with another non-coding pathogenic USH2A variant nearby, we analyzed in detail the 
deep intronic regions of this gene in solved cases harbouring this mutation. However, we were unable to identify 
any shared variant that met the criteria to be classified as pathogenic19. Therefore, if additional genetic load is acting 
together with the p.Cys759Phe, it is possibly that it is located in other regulatory regions.
Figure 2. USH2A mutations and genotype-phenotype correlations. (a) Schematic representation of usherin 
structure showing the mutated residues located within different protein domains. Isoform “a” is an N-terminal 
fragment of isoform “b”. Mutations in orange font are implicated in USHII, mutations in fuchsia font are 
associated with both non-syndromic RP and USHII and mutations in black font are associated with non-
syndromic RP. SP: signal peptide; LamGL: LamG-like jellyroll fold; Lam NT: Laminin N-terminal; EGFLam: 
Laminin-type EGF-like (LE); FN3: fibronectin type-III; LamG: Laminin G; TM: Transmembrane domain; 
PDB: PDZ-binding domain. (b) Phenotype-genotype correlations of usherin mutations. Variants responsible 
of non-syndromic RP are represented in blue. The variant p.Cys759Phe has been detected in combination with 
other deleterious alleles in nine patients with non-syndromic RP. Mutations shown in fuchsia color have been 
detected in individuals with both non-syndromic RP and USH depending on the nature of the second variant. 
Variants responsible of USHII are shown in orange.
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Among the other USH2A mutations, two of them (p.Glu767Serfs*21 and p.Arg303Ser) have been detected 
in both syndromic and non-syndromic RP patients (Families M, N, O and P). The expression of the phenotype 
varies depending on the nature of the second mutation. Therefore, the greater the impact on the protein function, 
the greater the likelihood of developing the most severe condition, in this case, USH. Remarkably, the affected 
members of family P were compound heterozygous for one CNV (duplication of exons 46–47) and one missense 
(p.Arg303Ser), previously reported to be causative of USHII61,63. The index patient (family P-II:9) presented, 
besides typical arRP, bilateral sensorineural hearing loss. These findings were consistent with a diagnosis of 
USHII. However, the other two affected siblings (II:1 and II:7) were diagnosed of non-syndromic RP. The fact that 
a specific combination of mutations may be associated with a wide spectrum of symptoms in the same family, can 
be explained by the modulating effects of other genes and/or environmental factors on phenotypic expression64.
The main aim of this study was to evaluate the contribution of deep-intronic variants in a cohort with a previ-
ously detected heterozygous mutation in ABCA4, USH2A and CEP290. In this regard, only two predicted path-
ogenic mutations might be considered to be disease-causing in one patient (Family S, Supplementary Fig. S1). 
Prediction reports of intronic variants must be interpreted with caution in a clinical context and functional stud-
ies are mandatory. Moreover, although a study involving a larger number of samples would help to clarify the 
role of deep-intronic variants in the aetiopathogenesis of IRDs, the results presented here seem to indicate that 
deep-intronic variants have a small contribution in this group of patients.
In summary, the possibility of sequencing a number of entire genes represented an intermediate strategy 
between targeted sequencing and whole-genome sequencing. However, due to the high prevalence of carriers of 
mutations in IRD genes in the general population, the large amount of data generated with this panel, and the 
results obtained in this study, sequencing entire genes do not seem to be the approach of choice for detecting the 
second hit in IRD patients with monoallelic variants.
Methods
Subjects and clinical evaluation. A total of 29 unrelated Spanish families with different IRDs were 
involved in this study, including all available family members for segregation analysis. This cohort was composed 
of 25 index patients with one previous known mutation in ABCA4, CEP290 or USH2A genes, and 4 IRDs patients 
that had not been studied before but with clinical suspicion of harbouring mutations in the genes included in 
the panel (Table 2). Prior to the study, written informed consents were obtained from all participants or their 
legal guardians. Study protocols followed the tenets of the Declaration of Helsinki and they were approved by the 
Institutional Review Boards of the University Hospital Virgen del Rocío (Seville, Spain).
Clinical diagnosis of retinal dystrophy was based on fundus examination, visual acuity, computerized testing 
of central and peripheral visual fields and electroretinography (ERG) findings. Furthermore, certain non-ocular 
features associated with retinal degenerations were evaluated in syndromic cases. Peripheral blood was collected 
from all subjects to extract genomic DNA using standard protocols. Previous analyses of the 25 subjects with 
known mutations were made by Asper Biotech Genotyping microarrays, Sanger sequencing of exon 13 of USH2A 
or by applying an earlier version of our custom panel9,30 (Table 2).
Custom panel development. Our IRDs custom panel was designed using the SeqCap EZ application of 
the NimbleDesign software (Roche, NimbleGen, Madison, WI, USA). The intended covered sequences com-
prised three whole genes (ABCA4, CEP290 and USH2A) known to have deep-intronic mutations associated 
with IRDs, as well as the coding exons and their adjacent 25 bp of 76 IRD genes (Supplementary Table S2). The 
genes were selected as previously described9; only those genes with pathogenic mutations in Spanish population 
were included. Besides, two known point mutations in deep-intronic regions of OFD1 (c.935 + 706 A > G) and 
PRPF31 (c.1374 + 654 C > G) were covered as well. A total of 1,239 regions were targeted, with a final panel size 
of 1,412,505 bp.
Library preparation and sequencing. DNA library was performed according to the manufacturer’s pro-
tocol (NimbleGen SeqCap EZ Library SR version 5.1, Roche). Briefly, 1 μg of genomic DNA was sheared using 
Covaris S220 (Covaris, Woburn, MA, USA) to obtain an average fragment size of 180–220 bp. A multiplex DNA 
library pool, generated by mixing identical amount of DNA from several samples, was captured. Quantification 
of libraries was made using Agilent 2100 Bionalyzer (Agilent Technologies, CA, USA), qPCR and fluorimetric 
techniques. Sequencing was performed on the Illumina’s MiSeq or NextSeq instruments (Illumina, San Diego, 
CA, USA) using a MiSeq v2 (300 cycles) and NextSeq Mid-output v2 (300 cycles) reagent kits.
Bioinformatic analysis. Data analysis was performed using our validated pipeline30 with some modifica-
tions. Burrows-Wheeler Aligner (BWA, version 0.7.12) was used to map sample reads against the hg19 human 
reference genome. BEDtools package (version 2.17.0) was used to analyze the percentage of reads on-target and 
the mean coverage in each sample. Duplicate reads were filtered out by employing PICARD’s MarkDuplicates 
command (version 1.95). Variant calling and filtering were carried out using GATK software (version 3.3.0) and 
reads with coverage <20X and strand bias (FS > 60.0) were discarded. SNVs and indels variants were then anno-
tated using wANNOVAR65, and only those with MAF < 0.015 in 1000G, Exome Variant Server (EVS), Exome 
Aggregation Consortium (ExAC), genome Aggregation Database (GnomAD) and dbSNP remained for further 
analysis. The frequency of all candidate variants was also checked in the Collaborative Spanish Variant Server 
(http://csvs.babelomics.org/) including a local population database that contains population frequency infor-
mation from the whole exomes of 267 unrelated individuals, representative of the healthy Spanish population 
(Medical Genome Project, MGP)66.
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Copy-Number Variations (CNVs) were identified employing the coverage command of BEDtools. In this 
method, the number of reads for each chromosomal interval of the bed file was normalized using the average 
number of reads generated per sample. These data were then compared with the corresponding data of the other 
samples in the same sequencing run. A ratio around 1 implied normal dosage; deletions and duplications ratios 
were set on <0.6 and >1.40 respectively. All CNVs were checked in Database of Genomic Variants (DGV) and 
DECIPHER67.
Variants prioritization and pathogenicity assesment. Prioritization was made with a step-by-step 
in-house pipeline. All variants of each sample were filtered by a Minor Allele Frequency (MAF) consistent with 
their disease (for IRD, MAF < 0.015). In patients with one known pathogenic variant in the coding sequence of 
ABCA4, CEP290 or USH2A, variants in these genes were prioritized. Heterozygous exonic, splicing and intronic 
variants were selected for further analysis, as well as variants with low coverage (<20X). For intronic and syn-
onymous variants, three online tools were used to assess splicing changes: NNSPLICE (http://www.fruitfly.org/
seq_tools/splice.html) and two algorithms included in Human Splicing Finder (HSF and MaxEntScan; http://
www.umd.be/HSF). Specific thresholds were defined based on a known deep-intronic variants validation study 
for two tools19: a minimum score of 2 and a score variation >15% for MaxEnt and a minimum score of 70 and 
score variation >10% for HSF, was necessary to pass the quality threshold. For NNSPLICE, we use default settings 
(cut-off >0.4) and a score difference between wild-type and mutated sequence >10% was needed to be consid-
ered for further analysis. The pathogenicity of novel candidate variants was predicted using Polyphen-2 (http://
genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.bii.a-star.edu.sg) and MutationTaster (www.mutationtaster.
org/). Clinical significance of known variants was also assessed using ClinVar (https://www.ncbi.nlm.nih.gov/
clinvar/) and/or Leiden Open Variation Database, LOVD (https://databases.lovd.nl/). Candidate variants were 
segregated in all available relatives by Sanger sequencing according to the manufacturer’s protocols (3730 DNA 
Analyzer, Applied Biosystems, Foster City, CA, USA).
To be considered causal variants, they must (i) segregate with the disease, (ii) be described as pathogenic or 
likely pathogenic in databases (ClinVar, OMIM) or be a novel mutation, or (iii) have clinical manifestations con-
sistent with the ones described for this variant. Large deletions and duplications were inspected with Integrative 
Genomics Viewer (IGV). If no candidate variants were found in these three entire genes, mutations in other loci 
were taken into account as described above. The nomenclature of variants was adjusted to the Human Genome 
Variation Society (http://varnomen.hgvs.org/) guidelines using Mutalyzer (https://mutalyzer.nl/).
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